An interventional study of Symplicity renal denervation system in Adults With Uncontrolled Hypertension, sponsored by Medtronic Vascular. Terminated at 1 site in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-07.
Sponsored by Medtronic Vascular · Not applicable, Interventional, and Treatment
This study is to evaluate efficacy and safety of renal denervation in the treatment of uncontrolled hypertension. This study will enroll a minimum of 40 and a maximum of 45 subjects. The study will be conducted at up to 8 actively enrolling investigational sites. The primary endpoint is change in Office Systolic Blood Pressure from baseline to 6 months post-procedure.
Estimated enrollment Start: May 2013 (estimated 90 day duration) Estimated last follow-up: September 2013 Follow-Up Duration: Subjects in the intent-to-treat population will be followed from enrollment through 6 months ±14 days for the effectiveness and safety endpoints
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 14 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Medtronic Vascular is the lead sponsor of 58 studies on the registry; 7 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Individual has renal artery anatomy that is ineligible for treatment including:
Device: Symplicity renal denervation system
Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure. A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator.
Efficacy: Change in Office Systolic Blood Pressure from baseline to 6 months post-procedure
Time frame: 6 months post procedure
Safety: Incidence of Major Adverse Events (MAE),through 6 months post-procedure
Time frame: 6 months post procedure
This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Vascular